ResultsIQ

ResultsIQ › Latest results › Sanofi Consumer Healthcare India Limited

Sanofi Consumer Healthcare India Limited Q3 FY26 results press release summary

NSE: SANOFICONR · BSE: 544250

Results press release of 28 Oct 2026, summarised by AI from the filing.

₹2,631 million, a growth of 12%, with domestic sales up 19%.

Key takeaways

  1. Q3 revenue ₹2,631 million, a growth of 12%, with domestic sales up 19%.
  2. Growth driver Volume expansion and market share gains across key brands, with brand building and wider distribution.
  3. Comparability Nine-month results not fully comparable with last year due to the 2024 recall and subsequent relaunches.

Original filing on BSE

Sanofi Consumer Healthcare India Limited Q2 FY27 results

As filed: Revenue ₹263 cr (+12% year on year), EBITDA ₹102 cr (+20% year on year), PAT ₹76.6 cr (+22% year on year), EBITDA margin 38.7% (+233 bps).

The Q2 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q1 FY27: Revenue ₹236 cr (+7% year on year), EBITDA ₹89.3 cr (+28% year on year), PAT ₹68.8 cr (+13% year on year), EBITDA margin 37.9% (+621 bps). Score 47 of 100, In line with trend. Revenue and profit growth were well below the company's own trend; EBITDA growth was below it. EBITDA margin rose 621 bps year on year. Revenue rose ₹14.7 cr on a year ago, against ₹57.0 cr the year before. Share price after the results: −11.8% in 30 days (Nifty 500: +1.6%).
  • Q4 FY26: Revenue ₹229 cr (+32% year on year), EBITDA ₹88.8 cr (+39% year on year), PAT ₹67.8 cr (+36% year on year), EBITDA margin 38.7% (+175 bps). Score 83 of 100, Above trend. EBITDA margin rose 175 bps year on year. Not enough history for a trend yet: scored on growth alone. Revenue fell 9% from last quarter. Share price after the results: −3.3% in 29 days (Nifty 500: +0.9%).
  • Q3 FY26: Revenue ₹251 cr (+47% year on year), EBITDA ₹89.8 cr (+45% year on year), PAT ₹66.5 cr (+51% year on year), EBITDA margin 35.8% (−48 bps). Score 85 of 100, Above trend. EBITDA margin fell 48 bps year on year. Not enough history for a trend yet: scored on growth alone. Share price after the results: +1.9% in 30 days (Nifty 500: −10.2%).
  • Q2 FY26: Revenue ₹234 cr (+46% year on year), EBITDA ₹85.0 cr (+35% year on year), PAT ₹63.0 cr (+40% year on year), EBITDA margin 36.3% (−305 bps). Score 76 of 100, Above trend. EBITDA margin fell 305 bps year on year. Not enough history for a trend yet: scored on growth alone. Share price after the results: −0.9% in 30 days (Nifty 500: −0.5%).
  • Q1 FY26: Revenue ₹221 cr (+35% year on year), EBITDA ₹70.0 cr (+11% year on year), PAT ₹61.0 cr (+110% year on year), EBITDA margin 31.7% (−674 bps). Score 68 of 100, Above trend. EBITDA margin fell 674 bps year on year. Not enough history for a trend yet: scored on growth alone. Share price after the results: +6.8% in 30 days (Nifty 500: 0.0%).
  • Q4 FY25: Revenue ₹173 cr, EBITDA ₹64.0 cr, PAT ₹50.0 cr, EBITDA margin 37.0%. Not scored. No result for the same quarter last year. Share price after the results: +4.9% in 30 days (Nifty 500: +3.7%).
  • Q3 FY25: Revenue ₹171 cr, EBITDA ₹62.0 cr, PAT ₹44.0 cr, EBITDA margin 36.3%. Not scored. No result for the same quarter last year.

Past price moves after results do not indicate future moves. Not a recommendation.

Sanofi Consumer Healthcare India Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.